Trial reportPsychiatry research2011
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.
Trial report in Psychiatry research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Pharmacotherapies for cannabis dependence.The Cochrane database of systematic reviews · 2019Pooled it
- Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.The Cochrane database of systematic reviews · 2018Pooled it
- Almost all antipsychotics result in weight gain: a meta-analysis.PloS one · 2014 · on this mapPooled it
- Pharmacotherapies for cannabis dependence.The Cochrane database of systematic reviews · 2014Pooled it
- Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis.The British journal of psychiatry : the journal of mental science · 2026Article
- Metabolic effects and clinical outcomes of olanzapine in schizophrenia: A systematic review and meta-analysis.Heliyon · 2024Review
- Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study.Schizophrenia bulletin · 2024Article
- Meta-Analysis of the Efficacy of Risperidone Treatment in Patients with First-Episode Schizophrenia.Noro psikiyatri arsivi · 2024Article
- Effects of olanzapine on anhedonia in schizophrenia: mediated by complement factor H.Frontiers in psychiatry · 2023Article
- Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders.Current addiction reports · 2014Article
- Anhedonia: a concept analysis.Archives of psychiatric nursing · 2013Review
- Treatment of substance abusing patients with comorbid psychiatric disorders.Addictive behaviors · 2012Review
- The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Journal of dual diagnosis · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
The purpose of this study is to compare the efficacy of olanzapine and risperidone for the acute treatment of first-episode schizophrenia patients with cannabis use disorders. This secondary analysis of a previously published study included 49 first-episode patients with a diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder and a co-occurring lifetime diagnosis of cannabis use disorders randomly assigned to treatment with either olanzapine (n=28) or risperidone (n=21) for 16weeks. The olanzapine group did not differ significantly from the risperidone group for initial response rates of positive symptoms, and rates of cannabis use or alcohol use during the study. Positive symptoms and the Scale for Assessment of Negative Symptoms (SANS) global asociality-anhedonia scores improved over time but did not differ between study medications. In both groups, cannabis use during the study was higher in patients who used cannabis within three months of the admission. Thus, our results suggest that olanzapine and risperidone had a similar initial efficacy on psychotic symptoms and substance use in first-episode patients with co-occurring cannabis use disorders. If clinicians are choosing between olanzapine versus risperidone treatment for this population, their decision should be based upon factors other than symptom response and short-term substance misuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.